PatentFizz is a site that claims to be a place where members of the community can comment on individual patents and it also has a few tricks up its sleeve.

They recently rolled out some improvements to their FirstPage Reports product, which gives you a single .pdf document containing the first page of every patent document in your project.

See an example of patents by Steve Jobs here.

The site also allows you to copy your USPTO search results and paste them directly into the Report order form. No matter the search, just copy everything from the results listing and paste it into the order form. The script will extract the numbers for every utility, design, and reissue patent – as well published applications – in the listing, and give you a link that lets you immediately download your Report.  There is also a screencast.

We think you’ll like these features.

  Print This Post Print This Post  

This week’s Blawg Review #134 is run by Eric Turkewitz at the New York Personal Injury Law Blog — it’s definitely a marathon.  Unfortunately, David Giacalone at f/k/a thinks that themed blawg reviews tend to be “annoying, strained and distracting.”

We especially enjoyed the Consumer Law & Policy Blog’s take on the Center for Consumer Freedom, an independent organization that advocates for consumers’ rights to make informed choices in the marketplace.  Well, as long as consumer freedom actually means a consumer’s ability to purchase products without adequate information about potential dangers and without adequate remedies if they are harmed.

We’re more concerned about Above the Law’s gossip on a judge that may have played a role in changing his kid’s bar exam grade from fail to pass. But, that’s another story.

We’ll have to see how Turkewitz fares as a trademark scofflaw

 

  Print This Post Print This Post  

bioohio 2007The IP Department of Frost Brown Todd LLC will once again be a sponsor of the BioOhio conference in Columbus, OH. This year’s BioOhio 2007 focus is “Devices & Diagnostics,” recognizing both sectors’ rapid growth and convergence with other bioscience fields.

On November 12, we convene with a networking reception featuring great food and drink, sponsors’ exhibit booths, door prizes, the 4th Annual Ohio Bioscience Student Poster Competition, and a first-time device/diagnostics product showcase.

The next day, November 13, features an agenda with local and national experts on advanced medical technology industry trends, regulatory issues, venture capital, and education, including FDA Clinical Deputy Director Ron Yustein, MD.

I’ll be there handing out Patent Baristas coffee mugs and Kona coffee.  Stop by and pick one up if you’re attending the conference.  

Special Offer: 

I have One (1) complimentary full registration for the BioOhio Conference.  If you’d like to take advantage of this offer, simply email me your name along with company, title and email address as soon as possible. 

The Fine print: 

One entry per person. We reserve the right to disqualify any entry that looks like it isn’t legitimate. The winner will be contacted at the email address given. Failure to respond within 24 hours will result in the registration being given to someone else. The winner will randomly be selected from all entries received by 5:00 pm (EST) on Friday, November 9th, 2007. Your email address will not be shared with any third party. Sorry, no refunds, substitutions or exchanges, not available to clients or family members and void where prohibited.

For more information on BioOhio 2007, contact Matt Schutte at 614/675-3686. See a full agenda or register online here.

See you in Columbus!

  Print This Post Print This Post  

You want to believe — at some deep, down gut level — that Congress will eventually listen to voices that matter when it comes to make changes in the law. But then, this is Congress.

Whether you love them or hate them, the venture capital industry is a force to be reckoned with. This is a group that put $25.5 billion into innovative companies in 2006 alone. This is also a group for which strong patent protection means the difference between payday and bankruptcy.

So it was only natural that some put in their two cents on the Patent Reform Act of 2007 (S. 1145), by sending a letter to the U.S. Senate Committee on the Judiciary addressing the concerns of emerging companies. They sum up their concerns as:

Suggesting a different approach to awarding damages based on a patent’s specific contribution over the prior art. the group suggests maintaining the current multi-factored analysis and defining limited circumstances in which apportionment may apply.

Arguing against the creation of a new proceeding within the U.S. Patent and Trademark Office to permit extended administrative challenges of validly-issued patents and supporting the approach in the House with one fixed post-grant opposition and an enhanced inter partes re-examination.

Arguing against curtailing the inequitable conduct defence and proposing the codification of a standard of clear and convincing evidence and a two-pronged test that specifies knowing and willful deception regarding material information and an objective standard for determining whether a claim would have issued absent the misconduct.

See the entire letter here:  Venture Groups Letter to Senate

Others like patent reform. The American Corn Growers Association (ACGA) , representing 14,000 members in 35 states, wrote their own letter to Congress letting them know that patent reform is critical. Pulling out the standard line used by politicians everywhere about how “family farmers” are being hurt, the group claims:

“Currently farmers are vulnerable to attack from biotech interests that sue family farmers for allegedly infringing on their patent rights due to actions that are often beyond their control,” explained Bolin. “ACGA urges quick passage of legislation that would help level the playing field for family farmers defending themselves against dubious claims of patent infringement.”

“Family farmers have been struggling for years against lawsuits that claim they have willfully infringed on the patents of genetically modified organisms (GMOs),” added Bolin. “These allegations of infringement are often unwarranted since farmers in many cases are sued after their fields are contaminated by pollen that naturally drifts over from a neighboring field. It has been proven that pollen (including GMOs) can drift more than five miles, which is impossible for an individual farmer to block or control in any way. Accordingly, these farmers should not be accused of ‘willfully’ infringing on the patent of seeds that naturally cross-pollinated into their fields.”

Bolin continued by stating, “Farmers should not be forced to travel hundreds of miles to another state to defend themselves against such allegations. To do so, often to defend themselves against unwarranted accusations, adds undue and often insurmountable financial stress on their modest family budgets. Currently the corporate plaintiffs in these cases often select courts in distant locations that favor them, which requires family farmers to travel to courts that are not only far away but also biased against them. The situation that farmers must endure today is clearly not the intent of the patent system and it should be corrected.”

Presumably, ACGA is referring to such cases Monsanto Canada Inc. v. Schmeiser, 2004 SCC 34, where the Supreme Court of Canada upheld the validity of a Monsanto patent. Despite an abundance of news articles perpetuating the view that this case was about an elderly gentleman haplessly planting a few plants in Mr. McGregor’s garden, as though it was his only sustenance, this case actually concerns a large scale, commercial farming operation that grew canola containing a patented cell and gene without obtaining license or permission. This is not about the innocent discovery by farmers of “blow-by” patented plants on their land or in their cultivated fields.

Schmeiser never purchased Roundup Ready Canola nor did he obtain a license to plant it. Yet, in 1998, tests revealed that 95 to 98 percent of his 1,000 acres of canola crop was made up of Roundup Ready plants. While the origin of the plants is unclear, the trial judge found that “none of the suggested sources [proposed by Schmeiser] could reasonably explain the concentration or extent of Roundup Ready canola of a commercial quality” ultimately present in Schmeiser’s crop.

For a U.S. case of seed saving, see Monsanto v. McFarling, where Monsanto went after the farmer for breaching a technology agreement by replanting genetically modified crops that resist glyphosphate herbicide.  In that case, McFarling saved 1500 bushels of Roundup Ready soybeans from his 1998 harvest and planted them the following year. He saved over 3000 bags of soybeans from his 1999 harvest for his next crop.

See more here:  ACGA Press Release

  Print This Post Print This Post  

The USPTO has released the list of organizations and persons that submitted comments in response to the July 2007 Rules of Practice Before the Board of Patent Appeals and Interferences in Ex Parte Appeals, Notice of Proposed Rule Making, first published in the Federal Register at 72 Fed. Reg. 41472 and then published in the Official Gazette at 1321 Off. Gaz. Pat. Office 95.

The USPTO claims that the proposed rule changes relating to rules of practice before the Board of Patent Appeals and Interferences in Ex Parte Appeals are needed to permit the Board to handle an increasing number of ex parte appeals in a timely manner, and has set forth five objectives for the proposed rule changes: (1) provide reviewers with a clear and complete statement of an appellant’s position at the time of filing an appeal brief; (2) minimize the pendency of appeals before the Office; (3) minimize the need for lengthy patent term adjustments; (4) provide uniform treatment of requests for an extension of time filed after an appeal brief is filed; and, (5) make the decision-making process more efficient.

Especially thoughtful and detailed comments are provided by the American Intellectual Property Law Association (AIPLA) and by David Boundy of Cantor Fitzgerald L.P.

In looking at the comments, it’s noteworthy that even IBM weighed in against the changes noting:

Even though we agree that the commitment to patent quality is a shared responsibility, we believe that some of the proposed rules are of questionable benefit and impose substantial, unjustified burdens on appellants.

Microsoft reiterated the point stating:

While we appreciate the USPTO’s efforts to make the appeal process more effective and timely, we fail to see a showing by the USPTO in the proposed changes how such objectives are accomplished, and thereby do not support the changes as proposed.

See the comments by Corporations and Associations:

  1. 3M Innovative Properties Company (3M IPC) [PDF]
  2. Alkermes, Inc. [PDF]
  3. Amylin Pharmaceuticals, Inc. [PDF]
  4. BIOCOM [PDF]
  5. Ceres [PDF]
  6. Eastman Kodak Company [PDF]
  7. Eli Lilly and Company [PDF]
  8. IBM Corporation [DOC]
  9. Microsoft Corporation [DOC]
  10. Wyeth [DOC]

See all the comments here.

  Print This Post Print This Post  

A new website popped up recently that is an attempt to serve as a global resource for dialogue on intellectual property rights and its role in advancing research and innovation.

The site, called Essential Innovation, is an online forum that will feature commentary and analysis on the importance of continued innovation, and the potential consequences a decline in intellectual property rights will have on global public health. This forum demonstrates cooperation to protect innovation from groups spread around the world, joining academic thought leaders, as well as scientists, researchers, doctors and inventors who create important advances in products and services.

The group believes that there has been an increase in attacks on intellectual property (IP) by nongovernmental organizations (NGOs) and governments. In a number of countries, notably Thailand and Brazil, recognized IP protections for life-saving medicines are being disregarded under the guise of promoting greater access. In addition, the World Health Organization (WHO) in November will also consider policy guidelines that significantly weaken IP protections on pharmaceuticals.

According to the group:

Patients around the world are in desperate need of new therapies to treat a variety of conditions. We need strong IP protection to encourage Brazil’s creative class, and the creative classes in countries around the world, to go for it and develop the next line of life-saving medicine.

This is an all-volunteer effort to provide a resource for anyone –media, NGOs, government officials, academics –looking for information from the scientists, researchers and inventors who are actually developing new medicine around the world. The Internet is littered with biased opinions about innovation from a small group of activists who have never done anything to advance science to save lives. This is most apparent in the claims from MSF, Oxfam and others that the patent system does not produce innovation. Nothing could be more patently absurd.

These issues are never as black and white as they seem — especially not as simple as the poll on the site puts it when it asks “Should one steal a medicine to extend a life?” and provides only a yes or no answer. This issue, like all of life, is complicated and often can only be answered with an “It depends.”

Read more here.

  Print This Post Print This Post  

mlrbody_01.gifThe Michigan Law Review’s companion journal First Impressions published an online symposium on the Supreme Court, the Federal Circuit, and Patent Law. The symposium is in light of recent Supreme Court decisions KSR v. Teleflex, Microsoft v. AT&T, and eBay v. MercExchange.

A diverse group of authors explores whether these cases, considered together, represent a recent upheaval in patent law and redefine the relationship between the Federal Circuit and the Supreme Court or if such predictions are overblown.

University of Michigan Law Professor Rebecca S. Eisenberg contends that the Federal Circuit’s control over patent law remains little diminished by the Court’s recent foray into the patent jurisprudence and argues that the most significant impact of KSR may be to embolden the U.S. Patent and Trademark Office to reject more patent applications for obviousness without fear of reversal.George Washington University Law Professor John F. Duffy argues that the Supreme Court’s reform of patent law substance and procedure was predictable and that KSR’s importance derives from the fact that it highlights many separate trends that are reshaping the patent system.

Patent litigator Harold C. Wegner believes that the Microsoft case revealed the balkanized nature of the Federal Circuit and that KSR, through which the Supreme Court created a unified message, will therefore be crucial to the Federal Circuit under future Chief Judge Randal Rader.

Senior Vice President and General Counsel for Eli Lilly & Co. Robert A. Armitage proposes that Congress adopt the National Academy of Sciences’ recommendations for reforming patent law rather than pursuing “anti-troll” objectives and simultaneously defends the judiciary’s successful track record of responding to common criticisms of anti-trolls without legislative intervention.

Patent litigators Stephen G. Kunin and Andrew K. Beverina explain KSR’s effect on patent law and outline lessons that it suggests for patent prosecution and litigation.

To download a PDF of the entire symposium, please click here.

Additional First Impressions content is available here.

  Print This Post Print This Post  

In the matter of Triantafyllos Tafas v. Jon W. Dudas, et al. consolidated with Smithkline Beecham Corporation, et al. v. Jon W. Dudas, et al. (1:07cv1008), the district court held that it was willing to grant GSK’s Motion for a Preliminary Injunction to enjoin enactment of the USPTO’s new rules, “Changes to Practice for Continued Examination Filings, Patent Applications Containing Patentably Indistinct Claims, and Examination of Claims in Patent Applications,” (Final Rules).

It is interesting to note that the USPTO fought against the injunction claiming that the public interest is most benefitted by the Final Rules going into effect immediately. The PTO claimed that the rules promote efficiency and timeliness and are needed immediately to alleviate the harm entrepreneurs suffer because of the current system’s uncertainty.

In addition, they argued that patent applicants who are preparing to comply with the Final Rules would face uncertainty as to how to proceed with patent prosecution and as to which rules would govern their application during the period of an injunction. [Note: If you’ve faced this great uncertainty, email me and I’ll send you a reassuring note back to soothe your fears.]

GSK countered that preserving the status quo while the litigation proceeds is important for maintaining stability for patent holders. Innovation is encouraged when patent holders and applicants have certainty about how their patents will be treated. The fact that three amicus briefs were filed by organizations representing a wide array of industries, all urging the Court to grant the preliminary injunction because their interests will otherwise be harmed, further demonstrated the possibility of potential immediate harm to the public if the rules were allowed to go into effect on November 1.

Fortunately, the court agreed with GSK noting:

Allowing the implementation of rules that may or may not remain in effect is likely to cause much greater uncertainty and squelching of innovation than a preliminary injunction giving the Court time to consider the validity of the Final Rules before they go into affect. Accordingly, the Court will find that the public interest is most served by continuing the status quo and granting the TRO.

Therefore, after considering the likelihood of GSK’s success on the merits, the possibility of irreparable harm to GSK if the injunction is not granted, the balance of hardships between the parties, and the public interest, the Court finds that GSK’s Motion should be granted.

GSK Preliminary Injunction Order (pdf)

  Print This Post Print This Post